{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:33:36Z","timestamp":1789180416332,"version":"build-2803163510"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["2021SK53519"],"award-info":[{"award-number":["2021SK53519"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ30791"],"award-info":[{"award-number":["2023JJ30791"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.biopha.2023.115239","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T10:37:25Z","timestamp":1690454245000},"page":"115239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["From bench to bedside: The promise of sotatercept in hematologic disorders"],"prefix":"10.1016","volume":"165","author":[{"given":"Zehao","family":"Lan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohua","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyun","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4535-3339","authenticated-orcid":false,"given":"Yichao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2023.115239_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01347-2022","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension","volume":"61","author":"HUMBERT","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"13","key":"10.1016\/j.biopha.2023.115239_bib2","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"HUMBERT","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.biopha.2023.115239_bib3","doi-asserted-by":"crossref","first-page":"7803","DOI":"10.1038\/s41598-022-11435-x","article-title":"Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension","volume":"12","author":"Joshi","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.115239_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ceb.2019.07.007","article-title":"TGF-beta signaling in cell fate control and cancer","volume":"61","author":"Yu","year":"2019","journal-title":"Curr. Opin. Cell Biol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115239_bib5","article-title":"The TGFbeta family in human placental development at the fetal-maternal interface","volume":"10","author":"Chuva","year":"2020","journal-title":"Biomolecules"},{"issue":"9","key":"10.1016\/j.biopha.2023.115239_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cells8090969","article-title":"TGFbeta\/BMP signaling pathway in cartilage homeostasis","volume":"8","author":"Thielen","year":"2019","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.biopha.2023.115239_bib7","doi-asserted-by":"crossref","DOI":"10.1242\/dev.188490","article-title":"TGFbeta family signaling and development","volume":"148","author":"Jia","year":"2021","journal-title":"Development"},{"issue":"5","key":"10.1016\/j.biopha.2023.115239_bib8","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41375-019-0420-1","article-title":"The role of TGFbeta in hematopoiesis and myeloid disorders","volume":"33","author":"Bataller","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.biopha.2023.115239_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/biom10030487","article-title":"TGF-beta signaling","volume":"10","author":"TZAVLAKI","year":"2020","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.biopha.2023.115239_bib10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1096\/fj.201600675r","article-title":"New function of the myostatin\/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration","volume":"31","author":"Pasteuning-Vuhman","year":"2017","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.biopha.2023.115239_bib11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12964-023-01201-5","article-title":"GDF-11 downregulates placental human chorionic gonadotropin expression by activating SMAD2\/3 signaling","volume":"21","author":"Wu","year":"2023","journal-title":"Cell Commun. Signal"},{"issue":"8","key":"10.1016\/j.biopha.2023.115239_bib12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/1933719109334967","article-title":"Activin A, activin receptor type II, nodal, and cripto mRNA are expressed by eutopic and ectopic endometrium in women with ovarian endometriosis","volume":"16","author":"TORRES","year":"2009","journal-title":"Reprod. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2023.115239_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000366152","article-title":"Activin signaling disruption in the cochlea does not influence hearing in adult mice","volume":"20","author":"HORVATH","year":"2015","journal-title":"Audio Neurootol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115239_bib14","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/blood-2015-01-622522","article-title":"RAP-011 improves erythropoiesis in zebrafish model of Diamond-Blackfan anemia through antagonizing lefty1","volume":"126","author":"Ear","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2023.115239_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2003.10.004","article-title":"The transforming growth factor-beta superfamily of receptors","volume":"15","author":"De Caestecker","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"issue":"9","key":"10.1016\/j.biopha.2023.115239_bib16","doi-asserted-by":"crossref","first-page":"a022061","DOI":"10.1101\/cshperspect.a022061","article-title":"TGF-beta signaling from receptors to smads","volume":"8","author":"Hata","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biopha.2023.115239_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cytogfr.2020.09.003","article-title":"Receptor binding competition: a paradigm for regulating TGF-beta family action","volume":"57","author":"Martinez-hackert","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"issue":"570","key":"10.1016\/j.biopha.2023.115239_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aav5183","article-title":"Specificity, versatility, and control of TGF-beta family signaling","volume":"12","author":"Derynck","year":"2019","journal-title":"Sci. Signal"},{"issue":"2","key":"10.1016\/j.biopha.2023.115239_bib19","doi-asserted-by":"crossref","first-page":"a022129","DOI":"10.1101\/cshperspect.a022129","article-title":"Non-smad signaling pathways of the TGF-beta family","volume":"9","author":"ZHANG","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"8","key":"10.1016\/j.biopha.2023.115239_bib20","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0301-472X(00)00488-4","article-title":"Transforming growth factor inhibits erythropoiesis by blocking proliferation and accelerating differentiation of erythroid progenitors","volume":"28","author":"Zermati","year":"2000","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115239_bib21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13287-020-01603-z","article-title":"Transforming growth factor beta1 accelerates and enhances in vitro red blood cell formation from hematopoietic stem cells by stimulating mitophagy","volume":"11","author":"Kuhikar","year":"2020","journal-title":"Stem Cell Res Ther."},{"issue":"4","key":"10.1016\/j.biopha.2023.115239_bib22","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nm.3524","article-title":"Targeting a new regulator of erythropoiesis to alleviate anemia","volume":"20","author":"PAULSON","year":"2014","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.biopha.2023.115239_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s43556-022-00109-9","article-title":"TGF-beta signal transduction: biology, function and therapy for diseases","volume":"3","author":"Tie","year":"2022","journal-title":"Mol. Biomed."},{"issue":"4","key":"10.1016\/j.biopha.2023.115239_bib24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nm.3468","article-title":"An activin receptor IIA ligand trap corrects ineffective erythropoiesis in beta-thalassemia","volume":"20","author":"DUSSIOT","year":"2014","journal-title":"Nat. Med"},{"issue":"2","key":"10.1016\/j.biopha.2023.115239_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020827","article-title":"Clinical and molecular insights in erythropoiesis regulation of signal transduction pathways in myelodysplastic syndromes and beta-thalassemia","volume":"22","author":"PARISI","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.biopha.2023.115239_bib26","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.3390\/ijms21155577","article-title":"RAP-011 rescues the disease phenotype in a cellular model of congenital dyserythropoietic anemia type ii by inhibiting the SMAD2-3 pathway","volume":"21","author":"De Rosa","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"25","key":"10.1016\/j.biopha.2023.115239_bib27","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/blood-2013-06-511238","article-title":"Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine beta-thalassemia","volume":"123","author":"Suragani","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.biopha.2023.115239_bib28","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.3512","article-title":"Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis","volume":"20","author":"Suragani","year":"2014","journal-title":"Nat. Med"},{"issue":"2","key":"10.1016\/j.biopha.2023.115239_bib29","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1172\/JCI133678","article-title":"Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes","volume":"130","author":"Verma","year":"2020","journal-title":"J. Clin. Invest"},{"issue":"6","key":"10.1016\/j.biopha.2023.115239_bib30","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/s41375-019-0448-2","article-title":"Transforming growth factor (TGF)-beta pathway as a therapeutic target in lower risk myelodysplastic syndromes","volume":"33","author":"Bewersdorf","year":"2019","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.biopha.2023.115239_bib31","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1073\/pnas.0911929107","article-title":"Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease","volume":"107","author":"Vallet","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.biopha.2023.115239_bib32","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20190206","article-title":"Activin A: a novel urinary biomarker of renal impairment in multiple myeloma","volume":"39","author":"Iriuchishima","year":"2019","journal-title":"Biosci. Rep."},{"issue":"10","key":"10.1016\/j.biopha.2023.115239_bib33","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/annonc\/mds068","article-title":"Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy","volume":"23","author":"Terpos","year":"2012","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2023.115239_bib34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jgg.2016.03.007","article-title":"A zebrafish model of 5q-syndrome using CRISPR\/Cas9 targeting RPS14 reveals a p53-independent and p53-dependent mechanism of erythroid failure","volume":"43","author":"Ear","year":"2016","journal-title":"J. Genet Genom."},{"issue":"6","key":"10.1016\/j.biopha.2023.115239_bib35","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1634\/stemcells.20-6-493","article-title":"The role of activin a in regulation of hemopoiesis","volume":"20","author":"Shav-tal","year":"2002","journal-title":"Stem Cells"},{"issue":"15","key":"10.1016\/j.biopha.2023.115239_bib36","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1182\/blood-2011-12-397067","article-title":"miR-21 mediates hematopoietic suppression in MDS by activating TGF-beta signaling","volume":"121","author":"Bhagat","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.biopha.2023.115239_bib37","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1158\/0008-5472.CAN-10-2933","article-title":"Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase","volume":"71","author":"Zhou","year":"2011","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.biopha.2023.115239_bib38","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/bjh.12838","article-title":"An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin","volume":"165","author":"Carrancio","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"543","key":"10.1016\/j.biopha.2023.115239_bib39","doi-asserted-by":"crossref","first-page":"eaaz5660","DOI":"10.1126\/scitranslmed.aaz5660","article-title":"ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension","volume":"12","author":"Yung","year":"2020","journal-title":"Sci. Transl. Med"},{"issue":"2","key":"10.1016\/j.biopha.2023.115239_bib40","doi-asserted-by":"crossref","first-page":"2002341","DOI":"10.1183\/13993003.02341-2020","article-title":"Targeting transforming growth factor-beta receptors in pulmonary hypertension","volume":"57","author":"Guignabert","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.biopha.2023.115239_bib41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ajh.23856","article-title":"RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice","volume":"90","author":"Langdon","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115239_bib42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12325-020-01524-6","article-title":"Burden of anemia in chronic kidney disease: beyond erythropoietin","volume":"38","author":"Hanna","year":"2021","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2023.115239_bib43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.exphem.2012.12.002","article-title":"Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap","volume":"41","author":"iancu-rubin","year":"2013","journal-title":"Exp. Hematol."},{"issue":"15","key":"10.1016\/j.biopha.2023.115239_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155438","article-title":"Mesenchymal stem cells in aplastic anemia and myelodysplastic syndromes: the \"seed and soil\" crosstalk","volume":"21","author":"Fattizzo","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2023.115239_bib45","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.kint.2016.07.039","article-title":"Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease","volume":"91","author":"Sugatani","year":"2017","journal-title":"[J. ]. Kidney Int"},{"key":"10.1016\/j.biopha.2023.115239_bib46","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bone.2018.02.026","article-title":"A soluble activin type IIA receptor mitigates the loss of femoral neck bone strength and cancellous bone mass in a mouse model of disuse osteopenia","volume":"110","author":"Lodberg","year":"2018","journal-title":"[J. ]. Bone"},{"issue":"3","key":"10.1016\/j.biopha.2023.115239_bib47","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3324\/haematol.2018.198887","article-title":"Sotatercept, a novel transforming growth factor beta ligand trap, improves anemia in beta-thalassemia: a phase II, open-label, dose-finding study","volume":"104","author":"Cappellini","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.biopha.2023.115239_bib48","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.hoc.2009.01.010","article-title":"The congenital dyserythropoietic anemias","volume":"23","author":"Renella","year":"2009","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"2","key":"10.1016\/j.biopha.2023.115239_bib49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00062752-200003000-00001","article-title":"Congenital dyserythropoietic anemias","volume":"7","author":"Wickramasinghe","year":"2000","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.biopha.2023.115239_bib50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pharmthera.2015.10.006","article-title":"Growth and differentiation factor 11 (GDF11): Functions in the regulation of erythropoiesis and cardiac regeneration","volume":"156","author":"Rochette","year":"2015","journal-title":"Pharm. Ther."},{"issue":"11","key":"10.1016\/j.biopha.2023.115239_bib51","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1111\/jcmm.15243","article-title":"Smad2\/3-pathway ligand trap luspatercept enhances erythroid differentiation in murine beta-thalassaemia by increasing GATA-1 availability","volume":"24","author":"Martinez","year":"2020","journal-title":"J. Cell Mol. Med"},{"key":"10.1016\/j.biopha.2023.115239_bib52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ctrv.2008.03.044","article-title":"P3. A soluble activin type II receptor prevents the development of myeloma bone disease","volume":"34","author":"Chantry","year":"2008","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"10.1016\/j.biopha.2023.115239_bib53","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood.2019001983","article-title":"GDF11 is not the target of luspatercept","volume":"134","author":"Camaschella","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.biopha.2023.115239_bib54","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood.2019001057","article-title":"Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of beta-thalassemia","volume":"134","author":"Guerra","year":"2019","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.biopha.2023.115239_bib55","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood.2019002066","article-title":"Steady-state and regenerative hematopoiesis occurs normally in mice in the absence of GDF11","volume":"134","author":"Goldstein","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.biopha.2023.115239_bib56","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.ekir.2019.08.001","article-title":"Sotatercept safety and effects on hemoglobin, bone, and vascular calcification","volume":"4","author":"Coyne","year":"2019","journal-title":"Kidney Int Rep."},{"issue":"11","key":"10.1016\/j.biopha.2023.115239_bib57","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/jcph.160","article-title":"Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women","volume":"53","author":"Sherman","year":"2013","journal-title":"J. Clin. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2023.115239_bib58","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.12835","article-title":"Sotatercept in patients with osteolytic lesions of multiple myeloma","volume":"165","author":"Abdulkadyrov","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115239_bib59","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1359\/jbmr.081208","article-title":"Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women","volume":"24","author":"Ruckle","year":"2009","journal-title":"J. Bone Min. Res"},{"issue":"1","key":"10.1016\/j.biopha.2023.115239_bib60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.biopha.2023.115239_bib61","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.phrs.2016.07.015","article-title":"Pharmacokinetics interactions of monoclonal antibodies","volume":"111","author":"Ferri","year":"2016","journal-title":"Pharm. Res"},{"issue":"16","key":"10.1016\/j.biopha.2023.115239_bib62","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.biopha.2023.115239_bib63","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1177\/0091270007308616","article-title":"Drug interaction studies of therapeutic proteins or monoclonal antibodies","volume":"47","author":"Mahmood","year":"2007","journal-title":"J. Clin. Pharm."},{"issue":"10","key":"10.1016\/j.biopha.2023.115239_bib64","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","article-title":"Population pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Dirks","year":"2010","journal-title":"Clin. Pharm."},{"issue":"10","key":"10.1016\/j.biopha.2023.115239_bib65","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1038\/s41375-021-01330-1","article-title":"Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia","volume":"35","author":"Renneville","year":"2021","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.biopha.2023.115239_bib66","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.749.749","article-title":"ACE-011, a soluble activin receptor type Iia IgG-Fc fusion protein, increases hemoglobin (Hb) and improves bone lesions in multiple myeloma patients receiving myelosuppressive chemotherapy: preliminary analysis","volume":"114","author":"Abdulkadyrov","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115239_bib67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tiv.2018.01.015","article-title":"TGFbeta1-mediated suppression of cytochrome P450(CYP) induction responses in rat hepatocyte-fibroblast co-cultures","volume":"50","author":"Yu","year":"2018","journal-title":"Toxicol. Vitr."},{"issue":"4","key":"10.1016\/j.biopha.2023.115239_bib68","first-page":"1517","article-title":"Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies","volume":"24","author":"Raftopoulos","year":"2016","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2023.115239_bib69","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/S2352-3026(18)30002-4","article-title":"Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial","volume":"5","author":"Komrokji","year":"2018","journal-title":"Lancet Haematol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223010302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223010302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:08:20Z","timestamp":1777878500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223010302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":69,"alternative-id":["S0753332223010302"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115239","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From bench to bedside: The promise of sotatercept in hematologic disorders","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115239"}}